Mar 14, 2024 8:00am EDT Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Jan 03, 2024 8:01am EST Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Dec 12, 2023 8:01am EST Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Dec 08, 2023 8:30am EST Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
Dec 01, 2023 8:01am EST Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
Nov 13, 2023 8:01am EST Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
Nov 02, 2023 7:01am EDT Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
Sep 07, 2023 8:01am EDT Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
Sep 05, 2023 8:01am EDT Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
